Champions Oncology, Inc. (CSBR) vs Kalaris Therapeutics Inc. (KLRS)

Champions Oncology, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Champions Oncology, Inc. and Kalaris Therapeutics Inc. are of similar size ($68.9M and $67.1M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −1.87%) and the higher return on invested capital (0.00% vs −626.2%). Across the 14 metrics below, Kalaris Therapeutics Inc. leads on 8 and Champions Oncology, Inc. on 6.

Valuation

Metric CSBR KLRS Biotechnology median
P/E n/m n/m 7.88
P/S 1.12 n/m 11.47
P/B 15.27 1.20 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 226.74 0.09 0.74
EV/Sales 1.16 n/m 10.73
Earnings yield (1.63%) (69.18%) (28.84%)
Free cash flow yield (8.98%) (58.83%) (23.03%)

Profitability

Metric CSBR KLRS Biotechnology median
Gross margin 49.82% 0.00% 65.16%
Operating margin (1.68%) 0.00% 0.00%
Net margin (1.87%) 0.00% 0.00%
Free cash flow margin (10.08%) 0.00% 0.00%
Return on equity (28.38%) (79.91%) (57.72%)
Return on assets (3.56%) (46.02%) (49.22%)
Return on invested capital (626.23%) 0.00% 0.00%

Growth

Metric CSBR KLRS Biotechnology median
Revenue growth (TTM) 6.65% — 5.64%
EPS growth (last fiscal year) (124.24%) 94.50% —
Revenue growth, 5-year CAGR 7.68% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSBR KLRS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.03 10.98 4.73
Net debt to EBITDA (20.56) 2.54 0.96

Dividend

Metric CSBR KLRS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CSBR KLRS Biotechnology median
Market cap 68.90m 67.05m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack